{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:00:31Z","timestamp":1794265231839,"version":"4.9.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13300-026-01863-7","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:38:33Z","timestamp":1775806713000},"page":"627-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fixed-Dose Combination Therapy as a Strategy to Improve Antidiabetic Medication Adherence in People with Type 2 Diabetes: A Narrative Review"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-5788","authenticated-orcid":false,"given":"Patrick J.","family":"Highton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-5999","authenticated-orcid":false,"given":"Mark P.","family":"Funnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-7099","authenticated-orcid":false,"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1863_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 11th Edition. 2025."},{"issue":"18","key":"1863_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson A-M, Kosiborod M, Pivodic A, Gudbj\u00f6rnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720\u201332.","journal-title":"N Engl J Med"},{"key":"1863_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","volume":"137","author":"K Khunti","year":"2018","unstructured":"Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137\u201348.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7258","key":"1863_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"issue":"1","key":"1863_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00125-024-06254-w","volume":"68","author":"K Khunti","year":"2025","unstructured":"Khunti K, Zaccardi F, Amod A, Aroda VR, Aschner P, Colagiuri S, et al. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. Diabetologia. 2025;68(1):17\u201328.","journal-title":"Diabetologia"},{"key":"1863_CR6","unstructured":"Sabat\u00e9 E. Adherence to long-term therapies: evidence for action: World Health Organization; 2003."},{"key":"1863_CR7","doi-asserted-by":"crossref","unstructured":"Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane database of systematic reviews. 2014(11).","DOI":"10.1002\/14651858.CD000011.pub4"},{"issue":"5","key":"1863_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691\u2013705.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1863_CR9","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2337\/dc16-1925","volume":"40","author":"K Khunti","year":"2017","unstructured":"Khunti K, Seidu S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care. 2017;40(11):1588\u201396.","journal-title":"Diabetes Care"},{"issue":"11","key":"1863_CR10","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/jdi.14285","volume":"15","author":"K Boonpattharatthiti","year":"2024","unstructured":"Boonpattharatthiti K, Songkla PN, Chantara J, Koomsri C, Krass I, Chaiyakunapruk N, et al. Prevalence of adherence to oral antidiabetic drugs in patients with type 2 diabetes: a systematic review and meta-analysis. Journal of Diabetes Investigation. 2024;15(11):1614\u201325.","journal-title":"Journal of Diabetes Investigation"},{"issue":"5","key":"1863_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"key":"1863_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00091","volume":"4","author":"P Kardas","year":"2013","unstructured":"Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1863_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/dme.12046","volume":"30","author":"JE Aikens","year":"2013","unstructured":"Aikens JE, Piette JD. Longitudinal association between medication adherence and glycaemic control in type 2 diabetes. Diabet Med. 2013;30(3):338\u201344.","journal-title":"Diabet Med"},{"key":"1863_CR14","doi-asserted-by":"crossref","unstructured":"DiBonaventura M, Wintfeld N, Huang J, Goren A. The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. Patient preference and adherence. 2014:873\u201382.","DOI":"10.2147\/PPA.S55550"},{"issue":"17","key":"1863_CR15","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/archinte.166.17.1836","volume":"166","author":"PM Ho","year":"2006","unstructured":"Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836\u201341.","journal-title":"Arch Intern Med"},{"issue":"7","key":"1863_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00125-024-06149-w","volume":"67","author":"S Denicol\u00f2","year":"2024","unstructured":"Denicol\u00f2 S, Reinstadler V, Keller F, Th\u00f6ni S, Eder S, Heerspink HJ, et al. Non-adherence to cardiometabolic medication as assessed by LC-MS\/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus. Diabetologia. 2024;67(7):1283\u201394.","journal-title":"Diabetologia"},{"issue":"2","key":"1863_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jphs.12016","volume":"4","author":"DT Juarez","year":"2013","unstructured":"Juarez DT, Tan C, Davis J, Mau M. Factors affecting sustained medication adherence and its impact on healthcare utilization in patients with diabetes. J Pharm Health Serv Res. 2013;4(2):89\u201394.","journal-title":"J Pharm Health Serv Res"},{"issue":"4","key":"1863_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/MLR.0b013e31820292d1","volume":"49","author":"JS Hong","year":"2011","unstructured":"Hong JS, Kang HC. Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea. Med Care. 2011;49(4):378\u201384.","journal-title":"Med Care"},{"key":"1863_CR19","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s11136-015-1006-7","volume":"24","author":"B-H Chew","year":"2015","unstructured":"Chew B-H. Medication adherence on quality of life among adults with type 2 diabetes mellitus: an exploratory analysis on the EDDMQoL study. Qual Life Res. 2015;24:2723\u201331.","journal-title":"Qual Life Res"},{"issue":"4","key":"1863_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s42000-022-00400-y","volume":"21","author":"A Chantzaras","year":"2022","unstructured":"Chantzaras A, Yfantopoulos J. Association between medication adherence and health-related quality of life of patients with diabetes. Hormones. 2022;21(4):691\u2013705.","journal-title":"Hormones"},{"key":"1863_CR21","doi-asserted-by":"crossref","unstructured":"Majeed A, Rehman M, Hussain I, Imran I, Saleem MU, Saeed H, et al. The impact of treatment adherence on quality of life among type 2 diabetes mellitus patients\u2013Findings from a cross-sectional study. Patient Prefer Adherence. 2021;475\u2013481.","DOI":"10.2147\/PPA.S295012"},{"issue":"1","key":"1863_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12877-023-03929-8","volume":"23","author":"H Yang","year":"2023","unstructured":"Yang H, Wu F, Gui M, Cheng Y, Zhang L. The role of medication adherence in the association between depressive symptoms and quality of life in older adults with type 2 diabetes mellitus. BMC Geriatr. 2023;23(1):196.","journal-title":"BMC Geriatr"},{"issue":"3","key":"1863_CR23","first-page":"148","volume":"8","author":"A Chandran","year":"2015","unstructured":"Chandran A, Bonafede MK, Nigam S, Saltiel-Berzin R, Hirsch LJ, Lahue BJ. Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus. Am Health Drug Benefits. 2015;8(3):148.","journal-title":"Am Health Drug Benefits"},{"issue":"10","key":"1863_CR24","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/s41591-024-03123-2","volume":"30","author":"EW Gregg","year":"2024","unstructured":"Gregg EW, Pratt A, Owens A, Barron E, Dunbar-Rees R, Slade ET, et al. The burden of diabetes-associated multiple long-term conditions on years of life spent and lost. Nat Med. 2024;30(10):2830\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1863_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"key":"1863_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.808190","volume":"13","author":"N Ab Rahman","year":"2022","unstructured":"Ab Rahman N, Lim MT, Thevendran S, Ahmad Hamdi N, Sivasampu S. Medication regimen complexity and medication burden among patients with type 2 diabetes mellitus: a retrospective analysis. Front Pharmacol. 2022;13:808190.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1863_CR27","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s13300-020-00838-6","volume":"11","author":"KS Boye","year":"2020","unstructured":"Boye KS, Mody R, Lage MJ, Douglas S, Patel H. Chronic medication burden and complexity for US patients with type 2 diabetes treated with glucose-lowering agents. Diabetes Ther. 2020;11(7):1513\u201325.","journal-title":"Diabetes Ther"},{"issue":"12","key":"1863_CR28","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2337\/dci23-0035","volume":"46","author":"K Khunti","year":"2023","unstructured":"Khunti K, Chudasama YV, Gregg EW, Kamkuemah M, Misra S, Suls J, et al. Diabetes and multiple long-term conditions: a review of our current global health challenge. Diabetes Care. 2023;46(12):2092\u2013101.","journal-title":"Diabetes Care"},{"issue":"8","key":"1863_CR29","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296\u2013310.","journal-title":"Clin Ther"},{"issue":"7","key":"1863_CR30","first-page":"527","volume":"18","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527\u201339.","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"1863_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychores.2013.11.003","volume":"76","author":"ST de Vries","year":"2014","unstructured":"de Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014;76(2):134\u20138.","journal-title":"J Psychosom Res"},{"key":"1863_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.curtheres.2017.01.005","volume":"84","author":"TM Vijayakumar","year":"2017","unstructured":"Vijayakumar TM, Jayram J, Cheekireddy VM, Himaja D, Teja YD, Narayanasamy D. Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review. Curr Ther Res Clin Exp. 2017;84:4\u20139.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"1863_CR33","doi-asserted-by":"publisher","DOI":"10.3402\/jchimp.v2i3.19081","volume":"2","author":"CC Quianzon","year":"2012","unstructured":"Quianzon CC, Cheikh IE. History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspect. 2012;2(3):19081.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"1863_CR34","first-page":"3","volume":"7","author":"R Levine","year":"1984","unstructured":"Levine R. Sulfonylureas: background and development of the field. Diabetes Care. 1984;7:3\u20137.","journal-title":"Diabetes Care"},{"issue":"Suppl1","key":"1863_CR35","first-page":"S4","volume":"16","author":"S Kalra","year":"2012","unstructured":"Kalra S, Sahay BK, Rao MS. Fixed dose combinations in diabetes: Indian innovation, Indian pride. Indian J Endocrinol Metab. 2012;16(Suppl1):S4\u20135.","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"1863_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/00325481.2020.1750228","volume":"132","author":"I Lingvay","year":"2020","unstructured":"Lingvay I, Beetz N, Sennewald R, Schuler-Metz A, Bertulis J, Loley C, et al. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med. 2020;132(4):337\u201345.","journal-title":"Postgrad Med"},{"issue":"10","key":"1863_CR37","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11883-023-01142-x","volume":"25","author":"N Ferri","year":"2023","unstructured":"Ferri N, Ruscica M, Santos RD, Corsini A. Fixed combination for the treatment of dyslipidaemia. Curr Atheroscler Rep. 2023;25(10):691\u20139.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"1863_CR38","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/jch.14009","volume":"22","author":"A Salam","year":"2020","unstructured":"Salam A, Huffman MD, Kanukula R, Hari Prasad E, Sharma A, Heller DJ, et al. Two\u2010drug fixed\u2010dose combinations of blood pressure\u2010lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens Greenwich. 2020;22(10):1769\u201379.","journal-title":"J Clin Hypertens Greenwich"},{"issue":"14","key":"1863_CR39","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1177\/2047487318789494","volume":"25","author":"VE Janssen","year":"2018","unstructured":"Janssen VE, Visseren FL, de Boer A, Grobbee DE, Westerink J, van der Graaf Y, et al. Combined use of polypill components in patients with type 2 diabetes mellitus. Eur J Prev Cardiol. 2018;25(14):1523\u201331.","journal-title":"Eur J Prev Cardiol"},{"key":"1863_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1558579","volume":"12","author":"H Yazgi","year":"2025","unstructured":"Yazgi H, Mattikalli S, Fang B, Heselton H, Ssentongo P, Farbaniec M. Efficacy of different polypill combinations for primary and secondary cardiovascular disease prevention: a systematic review and meta-analysis. Front Cardiovasc Med. 2025;12:1558579.","journal-title":"Front Cardiovasc Med"},{"key":"1863_CR41","unstructured":"Committee for Medicinal Products for Human Use. Guideline on clinical development of fixed combination medicinal products. European Medicines Agency. 2017."},{"key":"1863_CR42","unstructured":"US Food Drug Administration. Codevelopment of two or more new investigational drugs for use in combination. Guidance for industry US Department of Health and Human Services, Rockville, MD. 2013."},{"issue":"2","key":"1863_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.70098","volume":"15","author":"JM Elwing","year":"2025","unstructured":"Elwing JM, Barta S, Smith T, Rendon GG, Lopez D, Peters W, et al. Patient Perspectives on Fixed Dose Combination Therapy for Pulmonary Arterial Hypertension: Exploratory Focus Group Research. Pulmonary Circulation. 2025;15(2):e70098.","journal-title":"Pulmonary Circulation"},{"issue":"4","key":"1863_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/dom.12015","volume":"15","author":"D Bell","year":"2013","unstructured":"Bell D. Combine and conquer: advantages and disadvantages of fixed\u2010dose combination therapy. Diabetes Obes Metab. 2013;15(4):291\u2013300.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1863_CR45","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/03007995.2018.1551192","volume":"35","author":"R Nishimura","year":"2019","unstructured":"Nishimura R, Kato H, Kisanuki K, Oh A, Onishi Y, Guelfucci F, et al. Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):869\u201378.","journal-title":"Curr Med Res Opin"},{"key":"1863_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105782","volume":"171","author":"E Lazzaroni","year":"2021","unstructured":"Lazzaroni E, Nasr MB, Loretelli C, Pastore I, Plebani L, Lunati ME, et al. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res. 2021;171:105782.","journal-title":"Pharmacol Res"},{"issue":"5","key":"1863_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1463-1326.2011.01530.x","volume":"14","author":"J Wainstein","year":"2012","unstructured":"Wainstein J, Katz L, Engel S, Xu L, Golm G, Hussain S, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(5):409\u201318.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1863_CR48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1185\/03007995.2011.570745","volume":"27","author":"V Hutchins","year":"2011","unstructured":"Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157\u201368.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1863_CR49","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/ijcp.12071","volume":"67","author":"YC Hwang","year":"2013","unstructured":"Hwang YC, Kang M, Ahn C, Park J, Baik S, Chung D, et al. Efficacy and safety of glimepiride\/metformin sustained release once daily vs. glimepiride\/metformin twice daily in patients with type 2 diabetes. Int J Clin Pract. 2013;67(3):236\u201343.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1863_CR50","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.clinthera.2018.04.002","volume":"40","author":"J-D Kim","year":"2018","unstructured":"Kim J-D, Park C-Y, Cha B-Y, Ahn KJ, Kim IJ, Park KS, et al. Comparison of adherence to glimepiride\/metformin sustained release once-daily versus glimepiride\/metformin immediate release BID fixed-combination therapy using the medication event monitoring system in patients with type 2 diabetes. Clin Ther. 2018;40(5):752\u201361.","journal-title":"Clin Ther"},{"issue":"5","key":"1863_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250993","volume":"16","author":"A-K B\u00f6hm","year":"2021","unstructured":"B\u00f6hm A-K, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS ONE. 2021;16(5):e0250993.","journal-title":"PLoS ONE"},{"issue":"3","key":"1863_CR52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0149-2918(02)85047-0","volume":"24","author":"C Melikian","year":"2002","unstructured":"Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24(3):460\u20137.","journal-title":"Clin Ther"},{"issue":"12","key":"1863_CR53","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.clinthera.2004.12.018","volume":"26","author":"DR Vanderpoel","year":"2004","unstructured":"Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate\/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther. 2004;26(12):2066\u201375.","journal-title":"Clin Ther"},{"issue":"5","key":"1863_CR54","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11606-008-0544-x","volume":"23","author":"F Pan","year":"2008","unstructured":"Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611\u20134.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"1863_CR55","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.clinthera.2011.07.016","volume":"33","author":"JC Barner","year":"2011","unstructured":"Barner JC. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. Clin Ther. 2011;33(9):1281\u20138.","journal-title":"Clin Ther"},{"issue":"3","key":"1863_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3111\/13696998.2015.1109518","volume":"19","author":"T Lokhandwala","year":"2016","unstructured":"Lokhandwala T, Smith N, Sternhufvud C, S\u00f6rstadius E, Lee WC, Mukherjee J. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203\u201312.","journal-title":"J Med Econ"},{"issue":"10","key":"1863_CR57","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.clinthera.2008.10.003","volume":"30","author":"C Cheong","year":"2008","unstructured":"Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30(10):1893\u2013907.","journal-title":"Clin Ther"},{"issue":"1","key":"1863_CR58","volume":"2015","author":"G Rombopoulos","year":"2015","unstructured":"Rombopoulos G, Hatzikou M, Athanasiadis A, Elisaf M. Treatment compliance with fixed\u2010dose combination of vildagliptin\/metformin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: a 24\u2010week observational study. Int J Endocrinol. 2015;2015(1):251485.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"1863_CR59","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12325-011-0096-z","volume":"29","author":"M Benford","year":"2012","unstructured":"Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012;29(1):26\u201340.","journal-title":"Adv Ther"},{"issue":"1","key":"1863_CR60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1472-6963-12-270","volume":"12","author":"J Meddings","year":"2012","unstructured":"Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12(1):270.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"1863_CR61","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1345\/aph.1M426","volume":"44","author":"S Thayer","year":"2010","unstructured":"Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone\/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and\/or a sulfonylurea. Ann Pharmacother. 2010;44(5):791\u20139.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"1863_CR62","first-page":"958","volume":"28","author":"S Edelman","year":"2022","unstructured":"Edelman S, Cassarino D, Kayne D, Dex T, Li X, Pasquel FJ. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J Manag Care Spec Pharm. 2022;28(9):958\u201368.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1863_CR63","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1185\/03007995.2012.684045","volume":"28","author":"S Han","year":"2012","unstructured":"Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28(6):969\u201377.","journal-title":"Curr Med Res Opin"},{"key":"1863_CR64","doi-asserted-by":"publisher","first-page":"1156081","DOI":"10.3389\/fphar.2023.1156081","volume":"14","author":"Q Wei","year":"2023","unstructured":"Wei Q, Zhou J, Li H, Wang L, Wu Y, Ma A, et al. Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis. Front Pharmacol. 2023;14:1156081.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1863_CR65","doi-asserted-by":"publisher","first-page":"8","DOI":"10.36469\/jheor.2024.91396","volume":"11","author":"CJ Paoli","year":"2024","unstructured":"Paoli CJ, Linder J, Gurjar K, Thakur D, Wyckmans J, Grieve S. Effectiveness of single-tablet combination therapy in improving adherence and persistence and the relation to clinical and economic outcomes. J Health Econ Outcomes Res. 2024;11(1):8.","journal-title":"J Health Econ Outcomes Res"},{"issue":"11","key":"1863_CR66","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.4103\/jfmpc.jfmpc_843_20","volume":"9","author":"S Kalra","year":"2020","unstructured":"Kalra S, Das A, Priya G, Ghosh S, Mehrotra R, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: expert opinion from an international panel. J Family Med Primary Care. 2020;9(11):5450\u20137.","journal-title":"J Family Med Primary Care"},{"issue":"6","key":"1863_CR67","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jcjd.2019.05.005","volume":"43","author":"R Schlosser","year":"2019","unstructured":"Schlosser R. Fixed-dose and fixed-ratio combination therapies in type 2 diabetes. Can J Diabetes. 2019;43(6):440\u20134.","journal-title":"Can J Diabetes"},{"issue":"4","key":"1863_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40262-017-0589-2","volume":"57","author":"RP Dash","year":"2018","unstructured":"Dash RP, Rais R, Srinivas NR. Key pharmacokinetic essentials of fixed-dosed combination products: case studies and perspectives. Clin Pharmacokinet. 2018;57(4):419\u201326.","journal-title":"Clin Pharmacokinet"},{"key":"1863_CR69","doi-asserted-by":"publisher","first-page":"1528801","DOI":"10.3389\/fendo.2025.1528801","volume":"16","author":"S Wangnoo","year":"2025","unstructured":"Wangnoo S, Bhadada SK, Farishta F, Jayaram Naidu GG, Pattnaik I, Manohar K, et al. Safety and efficacy of fixed-dose combination of dapagliflozin and saxagliptin in patients with type 2 diabetes mellitus\u2013a phase 4 study in India. Front Endocrinol. 2025;16:1528801.","journal-title":"Front Endocrinol"},{"issue":"9","key":"1863_CR70","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/dom.13352","volume":"20","author":"R Kawamori","year":"2018","unstructured":"Kawamori R, Haneda M, Suzaki K, Cheng G, Shiki K, Miyamoto Y, et al. Empagliflozin as add\u2010on to linagliptin in a fixed\u2010dose combination in Japanese patients with type 2 diabetes: glycaemic efficacy and safety profile in a 52\u2010week, randomized, placebo\u2010controlled trial. Diabetes Obes Metab. 2018;20(9):2200\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1863_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3752","volume":"40","author":"R Wang","year":"2024","unstructured":"Wang R, Luo S, Xiao Z, Zhou Z. Efficacy and safety of fixed\u2010ratio combination insulin degludec\/liraglutide in type 2 diabetes: a systematic review and meta\u2010analysis of randomised controlled trials. Diabetes Metab Res Rev. 2024;40(3):e3752.","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"1863_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70059","volume":"41","author":"C Irace","year":"2025","unstructured":"Irace C, Avogaro A, Bertuzzi F, Buzzetti R, Candido R, Del Prato S, et al. Enhancing type 2 diabetes care with CGM integration: insights from an Italian expert group. Diabetes Metab Res Rev. 2025;41(5):e70059.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"1863_CR73","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.pec.2019.10.008","volume":"103","author":"G Milky","year":"2020","unstructured":"Milky G, Thomas J III. Shared decision making, satisfaction with care and medication adherence among patients with diabetes. Patient Educ Couns. 2020;103(3):661\u20139.","journal-title":"Patient Educ Couns"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01863-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01863-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01863-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:27:41Z","timestamp":1778581661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01863-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1863"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01863-7","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kamlesh Khunti has acted as a consultant, speaker or received grants for investigator-initiated studies for Astra Zeneca, Bayer, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme, Boehringer Ingelheim, Oramed Pharmaceuticals, Pfizer, Roche, Daiichi-Sankyo and Applied Therapeutics, as well as honoraria from Servier. Patrick Highton has received honoraria from Servier. Mark Funnell has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}